Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724386 · ClinicalTrials.gov registry record · Phase 1
Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer
A Phase 1 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT00724386 is a Phase 1 study that has completed, run by University of Chicago. The registered enrollment target is 26 participants.
The verdict
NCT00724386, a Phase 1 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The goal of this study is to determine the feasibility based on toxicity and response rate of giving paclitaxel weekly with concomitant every-other week radiotherapy to limit skin toxicity. This study will also seek to determine the maximally tolerated dose of Navelbine added to this combination when followed by Filgrastim and the dose-limiting toxicities of this regimen.
Interventions
- DRUG Paclitaxel
- RADIATION Radiation
- DRUG Filgrastim
- DRUG Vinorelbine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 1999-06 |
| Est. Completion | 2012-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724386
The ClinicalTrials.gov registry entry for NCT00724386 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Paclitaxel is the first listed.
NCT00724386 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724386 about?
NCT00724386 is a clinical study titled "Concomitant Chemoradiotherapy With Weekly Paclitaxel and Vinorelbine and Granulocyte Colony Stimulating Factor (GCSF) Support in Patients With Advanced Breast Cancer". The goal of this study is to determine the feasibility based on toxicity and response rate of giving paclitaxel weekly with concomitant every-other week radiotherapy to limit skin toxicity. This study will also seek to determine the maximally tolerated dose of Navelbine added to this combination whe...
What is the current status of trial NCT00724386?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 1999-06. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00724386?
The interventions under investigation include: Paclitaxel (DRUG), Radiation (RADIATION), Filgrastim (DRUG), Vinorelbine (DRUG).
Who is sponsoring clinical trial NCT00724386?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.